格隆汇8月27日丨盈康生命(300143.SZ)在投资者互动平台表示，公司始终密切关注全球医疗科技领域的 前沿动态与发展趋势，包括脑机接口等技术在医疗健康场景的应用可能性。公司旗下运城医院完成23例 脑起搏器植入术（DBS），为帕金森患者提供创新治疗方案。同时，率先引进"方向电极"技术（精准 DBS），解决传统高频刺激的副作用问题，并开展"asleep DBS"（全麻下DBS）创新术式，降低患者术 中应激反应，拓展高龄患者适应症，医院手术量居山西省前列，区域辐射效应凸显。未来，公司将积极 论证和探索深层次脑机接口技术落地的可行性，从神经康复、疑难脑病诊疗切入，推进阿尔茨海默病、 卒中后遗症、帕金森等神经系统疾病诊疗技术提升。 ...

Core Viewpoint - The company is actively monitoring advancements in global medical technology, particularly the application of brain-computer interface technologies in healthcare settings [1] Group 1: Company Developments - The company’s hospital has successfully completed 23 deep brain stimulation (DBS) surgeries, providing innovative treatment options for Parkinson's patients [1] - The introduction of "directional electrodes" technology addresses the side effects associated with traditional high-frequency stimulation [1] - The company has pioneered the "asleep DBS" technique, which reduces intraoperative stress responses and expands the eligibility for elderly patients [1] Group 2: Market Position and Future Plans - The hospital ranks among the top in surgical volume in Shanxi Province, indicating a significant regional impact [1] - The company plans to explore the feasibility of advanced brain-computer interface technologies, focusing on neurological rehabilitation and treatment of complex brain diseases [1] - Future initiatives will aim to enhance diagnostic and treatment technologies for Alzheimer's disease, post-stroke sequelae, and Parkinson's disease [1]